ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO407

Urinary Prostaglandin E2 Excretion Is Associated With Disease Progression in Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic


  • Geurts, Frank, Erasmus MC, Rotterdam, Netherlands
  • Messchendorp, A. Lianne, University Medical Center Groningen, Groningen, Netherlands
  • Gansevoort, Ron T., University Medical Center Groningen, Groningen, Netherlands
  • Meijer, Esther, University Medical Center Groningen, Groningen, Netherlands
  • Zietse, Robert, Erasmus MC, Rotterdam, Netherlands
  • Salih, Mahdi, Erasmus MC, Rotterdam, Netherlands
  • Fenton, Robert A., Aarhus Universitet, Aarhus, Midtjylland, Denmark
  • Hoorn, Ewout J., Erasmus MC, Rotterdam, Netherlands

In cell and animal models of autosomal dominant polycystic kidney disease (ADPKD) cyst growth is enhanced by prostaglandin E2 (PGE2). Here, we hypothesize that higher urinary PGE2 excretion in patients with ADPKD is associated with faster disease progression.


We used samples from the DIPAK study, a prospective multi-center cohort of patients with ADPKD, and measured 24h urine PGE2 and its metabolites (PGEM). Linear mixed models were used to analyze the association of PGE excretion with disease progression assessed by eGFR slope. The relation between urinary PGE excretion and a composite outcome of 40% loss of eGFR or kidney failure was analyzed using Cox regression models. PGE excretions were log transformed prior to analysis.


Urinary PGE2 and PGEM excretion was measured in 590 patients (48±12 years, eGFR 73±28 ml/min/1.73m2) and independently associated with height adjusted total kidney volume (htTKV, β 0.10 p=0.04). A total of 504 patients were available for the eGFR slope and survival analysis (median of 4.2 eGFR measurements and 3.1 years of follow-up). The mean eGFR slope in the linear mixed model was -2.9 ml/min/1.73m2/year. A higher urinary excretion of PGE2 and PGEM were both significantly associated with faster eGFR decline. When correcting for htTKV, this effect persisted for PGEM (Table). Higher urinary PGE2 (HR 2.02 p=0.02) and PGEM (HR 3.65 p=0.008) excretion was associated with a higher incidence of kidney failure or 40% loss of eGFR after correcting for baseline characteristics, but this effect lost statistical significance after correction for htTKV (PGE2: HR 1.75 p=0.12, PGEM: HR 2.51 p=0.051).


Higher urinary PGE2 and PGEM excretion is associated with faster eGFR decline in ADPKD. The relation of PGE2 with htTKV suggests cyst-related production. Our findings suggest that in patients with ADPKD, PGE2 and PGEM should be further investigated as markers of disease progression or even as potential therapeutic targets.

Table 1: Linear mixed model of urinary PGE and PGEM excretion with eGFR slope.
 Model 1Model 2Model 3
PGE2 ng/24h-1.20.001-1.20.002-0.240.5
PGEM ng/24h-1.9<0.001-1.50.004-1.110.03

model1: unadjusted, model2: adjusted for age, sex BMI, albuminuria and PKD mutation, model3: model2+hTKV